Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3074828 in Moderate to Severe Plaque Psoriasis (Protocol I6T-MC-AMAF)
2016-001098-34Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of mirikizumab in plaque psoriasis, sponsored by Eli Lilly and Company. Started Jul 2016; status: completed.
02
Drugs
mirikizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2016-001098-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001098-34.